key: cord-0283587-qlwergum
authors: Tada, Takuya; Zhou, Hao; Dcosta, Belinda M.; Samanovic, Marie I.; Mulligan, Mark J.; Landau, Nathaniel R.
title: SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
date: 2021-07-03
journal: bioRxiv
DOI: 10.1101/2021.07.02.450959
sha: 08f57e6d1445a3809c32b6cc0acedadcc8c31dd4
doc_id: 283587
cord_uid: qlwergum

The SARS-CoV-2 lambda variant (lineage C.37) was designated by the World Health Organization as a variant of interest and is currently increasing in prevalence in South American and other countries. The lambda spike protein contains novel mutations within the receptor binding domain (L452Q and F490S) that may contribute to its increased transmissibility and could result in susceptibility to re-infection or a reduction in protection provided by current vaccines. In this study, the infectivity and susceptibility of viruses with the lambda variant spike protein to neutralization by convalescent sera and vaccine-elicited antibodies was tested. Virus with the lambda spike had higher infectivity and was neutralized by convalescent sera and vaccine-elicited antibodies with a relatively minor 2.3-3.3-fold decrease in titer on average. The virus was neutralized by the Regeneron therapeutic monoclonal antibody cocktail with no loss of titer. The results suggest that vaccines in current use will remain protective against the lambda variant and that monoclonal antibody therapy will remain effective.

The continued emergence of severe acute respiratory syndrome coronavirus 2 (SARSneutralization of the variant spike protein, we generated expression vectors for the variant 66 and its constituent mutations and used these to produce pseudotyped lentiviral virions 67 encoding GFP and nano-luciferase reporters. The use of such pseudotypes to determine 68 antibody neutralizing titers has been shown to yield results consistent with those obtained 69 with the live virus plaque reduction neutralization test 10 to the L452Q and F490S mutations in the lambda spike protein ( Figure 1A , B, C). 91 92 L452Q increases spike protein affinity for ACE2. N501Y and L452R mutations in the 93 RBD of earlier variants increase spike protein affinity for ACE2, an effect that most likely 94 is a primary contributor to the increased transmissibility of the alpha, beta and delta 95 variants 11 . To determine whether the lambda variant has an increased affinity for ACE2, 96

we used a sACE2 neutralization assay in which pseudotyped virions were incubated with 97 different concentrations of sACE2 and the infectivity of the treated virions was measured 98 on ACE2.293T cells. The results showed that the lambda spike caused a 3-fold increase 99 sACE2 binding. The increase was caused by the L452Q mutation and was similar to the 100 increase provided by the N501Y mutation 12,13 ( Figure 1D ). The F490S mutation did not 101 have a detectable effect on sACE2 binding. The findings suggest that L452Q, like L452R 102 in the delta variant, increases virus affinity for ACE2, likely contributing to increased 103 transmissibility.

neutralized by REGN10933 with no decrease in titer. The REGN10933 and REGN10987 111 cocktail neutralized the virus with no decrease in titer relative to virus with the D614G 112 spike protein (Figure 2A and B) . 113 partial resistance to neutralization by vaccine-elicited antibodies and convalescent sera; 118 however the average 3-fold decrease in neutralizing titer against the variant is not likely 119 to cause a significant loss of protection against infection as the average neutralization 120 IC50 titer by the sera of BNT162b2 and mRNA-1273 vaccinated individuals was about 121 1:600, a titer that is above that in the sera of individuals who recovered from infection with 122 the parental D614G virus. A small fraction of vaccinated individuals had serum antibody 123 titers less than average but whether this will lead to reduced protection from variant 124 infection will need to be determined in epidemiological studies. 

The authors declare no competing interests. 

All experiments were in technical duplicates or triplicates and the data were analyzed 238 using GraphPad Prism 8. Statistical significance was determined by the two-tailed, 239 unpaired t-test. Significance was based on two-sided testing and attributed to p< 0.05. 240

Confidence intervals are shown as the mean ± SD or SEM. (*P≤0.05, **P≤0.01, 241 ***P≤0.001, ****P≤0.0001). The PDB file of SARS-CoV-2 spike protein (7BNM) 15 

REGN-COV2, a Neutralizing European, South African, and United States SARS-CoV-2 variant spike proteins 249 by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Antibody resistance of SARS-CoV-2 variants

351 and B.1.1.7. Nature 2021

Neutralization of SARS-CoV-2 spike 69/70 deletion, 254 E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Multiple SARS-CoV-2 variants 257 escape neutralization by vaccine-induced humoral immunity

SARS-CoV-2 501Y.V2 escapes 260 neutralization by South African COVID-19 donor plasma

Serum Neutralizing Activity Elicited by mRNA-263

Transmission, infectivity, and 284 neutralization of a spike L452R SARS-CoV-2 variant